Autologous antibody to src-homology 3-domain GRB2-like 1 specifically increases in the sera of patients with low-grade gliomas

Journal of Experimental and Clinical Cancer Research

Volumn 31, Issue 1, 2012, Pages

  Matsutani, Tomoo ^a   Hiwasa, Takaki ^a   Takiguchi, Masaki ^a   Oide, Takashi ^a   Kunimatsu, Mitoshi ^b   Saeki, Naokatsu ^a   Iwadate, Yasuo ^a  

^a CHIBA UNIVERSITY   (Japan)

^b NAGOYA WOMEN'S UNIVERSITY   (Japan)

Author keywords

Autoantibody; Glioma; SEREX; SH3GL1; Src

Indexed keywords

ANTIBODY; ANTIGEN; COMPLEMENTARY DNA; EPITOPE;

AMINO ACID SEQUENCE; ANIMAL CELL; ANTIBODY BLOOD LEVEL; ARTICLE; ASTROCYTOMA; CANCER CELL CULTURE; CANCER GRADING; CHOROID PLEXUS TUMOR; CLONING; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPENDYMOMA; GENE DELETION; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SEROLOGY; SERUM; SRC HOMOLOGY DOMAIN;

ANIMALS; ANTIBODIES; ANTIBODY SPECIFICITY; ANTIGENS, NEOPLASM; BRAIN NEOPLASMS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; EPITOPES; GENE LIBRARY; GLIOMA; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASM GRADING; RATS; REPRODUCIBILITY OF RESULTS;

EID: 84867237102     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-31-85     Document Type: Article

References (37)

1. Epidemiology and etiology of gliomas. Ohgaki H, Kleihues P, Acta Neuropathol 2005 109 93 108 10.1007/s00401-005-0991-y 15685439
2. Randomized Phase III controlled trials of therapy in malignant glioma: where are we after 40 years? Anderson E, Grant R, Lewis SC, Whittle IR, Br J Neurosurg 2008 22 339 349 10.1080/02688690701885603 18568722
3. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. van den Bent MJ, Afra D, de Witte O, Ben Hassel M, Schraub S, Hoang-Xuan K, Malmstrom PO, Collette L, Pierart M, Mirimanoff R, Karim AB, Lancet 2005 366 985 990 10.1016/S0140-6736(05)67070-5 16168780
4. Glioma extent of resection and its impact on patient outcome. Sanai N, Berger MS, Neurosurgery 2008 62 753 764 10.1227/01.neu.0000318159.21731.cf 18496181
5. Human neoplasms elicit multiple specific immune responses in the autologous host. Sahin U, Tureci O, Schmitt H, Cochlovius B, Johannes T, Schmits R, Stenner F, Luo G, Schobert I, Pfreundschuh M, Proc Natl Acad Sci U S A 1995 92 11810 11813 10.1073/pnas.92.25.11810 8524854
6. Analysis of the antibody repertoire of astrocytoma patients against antigens expressed by gliomas. Schmits R, Cochlovius B, Treitz G, Regitz E, Ketter R, Preuss KD, Romeike BF, Pfreundschuh M, Int J Cancer 2002 98 73 77 10.1002/ijc.10170 11857388
7. Autoantibodies against GLEA2 and PHF3 in glioblastoma: tumor-associated autoantibodies correlated with prolonged survival. Pallasch CP, Struss AK, Munnia A, Konig J, Steudel WI, Fischer U, Meese E, Int J Cancer 2005 117 456 459 10.1002/ijc.20929 15906353
8. Identification of a human glioma antigen, SOX6, recognized by patients' sera. Ueda R, Iizuka Y, Yoshida K, Kawase T, Kawakami Y, Toda M, Oncogene 2004 23 1420 1427 10.1038/sj.onc.1207252 14691456
9. Primary brain tumors in adults. Behin A, Hoang-Xuan K, Carpentier AF, Delattre J-Y, Lancet 2003 361 323 331 10.1016/S0140-6736(03)12328-8 12559880
10. The SH2 and SH3 domains of mammalian Grb2 coupled the EGF receptor to the Ras activator mSos1. Rozakis-Adcock M, Fernley R, Wade J, Pawson T, Bowtell D, Nature 1993 363 83 85 10.1038/363083a0 8479540
11. Aberrant G protein signaling in nervous system tumors. Woods SA, Marmor E, Feldkamp M, Lau N, Apicelli AJ, Boss G, Gutmann DH, Guha A, J Neurosurg 2002 97 627 642 10.3171/jns.2002.97.3.0627 12507109
12. Genetic pathways to glioblastoma: a population-based study. Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL, Burkhard C, Schüler D, Probst-Hensch NM, Maiorka PC, Baeza N, Pisani P, Yonekawa Y, Yasargil MG, Lütolf UM, Kleihues P, Cancer Res 2004 64 6892 6899 10.1158/0008-5472.CAN-04-1337 15466178
13. Peptide array-based interaction assay of solid-bound peptides and anchorage-dependent cells and its effectiveness in cell-adhesive peptide design. Kato R, Kaga C, Kunimatsu M, Kobayashi T, Honda H, J Biosci Bioeng 2006 101 485 495 10.1263/jbb.101.485 16935250
14. Glioma invasion in the central nervous system. Giese A, Westphal M, Neurosurgery 1996 39 235 252 10.1097/00006123-199608000-00001 8832660
15. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by a abnormalities in PDGFRA, IDH1, EGFR, and NF1. Verhaak RG, Hoadley KA, Purdom E, et al. Cancer Cell 2010 17 98 110 10.1016/j.ccr.2009.12.020 20129251
16. EEN encodes for a member of a new family of proteins containing an Src homology 3 domain and is the third gene located on chromosome 19p13 that fuses to MLL in human leukemia. So CW, Caldas C, Liu MM, Chen SJ, Huang QH, Gu LJ, Sham MH, Wiedemann LM, Chan LC, Proc Natl Acad Sci U S A 1997 94 2563 2568 10.1073/pnas.94.6.2563 9122235
17. Identification and characterization of EBP, a novel EEN binding protein that inhibits Ras signaling and is recruited into the nucleus by the MLL-EEN fusion protein. Yam JW, Jin DY, So CW, Chan LC, Blood 2004 103 1445 1453 14551139
18. Aberrant transcriptional regulation of the MLL fusion partner EEN by AML1-ETO and its implication in leukemogenesis. Ma LH, Liu H, Xiong H, Chen B, Zhang XW, Wang YY, Le HY, Huang QH, Zhang QH, Li BL, Chen Z, Chen SJ, Blood 2007 109 769 777 10.1182/blood-2006-02-003517 16990610
19. Subcellular localization of EEN/endophilin A2, a fusion partner gene in leukaemia. Cheung N, So CW, Yam JW, So CK, Poon RY, Jin DY, Chan LC, Biochem J 2004 383 27 35 10.1042/BJ20040041 15214844
20. A novel SH3-containing human gene family preferentially expressed in the central nervous system. Giachino C, Lantelme E, Lanzetti L, Saccone S, Bella Valle G, Migone N, Genomics 1997 41 427 434 10.1006/geno.1997.4645 9169142
21. Expression and protein-binding studies of the EEN gene family, new interacting partners for dynamin, synaptojanin and huntingtin proteins. So CW, Sham MH, Chew SL, Cheung N, So CK, Chung SK, Caldas C, Wiedemann LM, Chan LC, Biochem J 2000 348 Pt 2 447 458 10816441
22. The SH3p4/Sh3p8/SH3p13 protein family: binding partners for synaptojanin and dynamin via a Grb2-like Src homology 3 domain. Ringstad N, Nemoto Y, De Camilli P, Proc Natl Acad Sci U S A 1997 94 8569 8574 10.1073/pnas.94.16.8569 9238017
23. Differential expression of endophilin 1 and 2 dimers at central nervous system synapses. Ringstad N, Nemoto Y, De Camilli P, J Biol Chem 2001 276 40424 40430 10.1074/jbc.M106338200 11518713
24. Human glioma-induced immunosuppression involves soluble factor(s) that alters monocyte cytokine profile and surface markers. Zou JP, Morford LA, Chougnet C, Dix AR, Brooks AG, Torres N, Shuman JD, Coligan JE, Brooks WH, Roszman TL, Shearer GM, J Immunol. 1999 162 4882 4892 10202033
25. Mechanisms of malignant glioma immune resistance and sources of immunosuppression. Gomez GG, Kruse CA, Gene Ther Mol Biol 2006 10 133 146 16810329
26. Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. Mapara MY, Sykes M, J Clin Oncol 2004 22 1136 1151 10.1200/JCO.2004.10.041 15020616
27. Glioma-associated cancer initiating cells induce immunosuppression. Wei J, Barr J, Kong L-Y, Wang Y, Wu A, Sharma AK, Gumin J, Henry V, Colman H, Sawaya R, Lang FF, Heimberger AB, Clin Cancer Res 2010 16 461 473 10.1158/1078-0432. CCR-09-1983 20068105
28. Hallmarks of cancer: the next generations. Hanahan D, Weinberg RA, Cell 2011 144 646 674 10.1016/j.cell.2011.02.013 21376230
29. Serological identification of TROP2 by recombinant cDNA expression cloning using sera of patients with esophageal squamous cell carcinoma. Nakashima K, Shimada H, Ochiai T, Kuboshima M, Kuroiwa N, Okazumi S, Matsubara H, Nomura F, Takiguchi M, Hiwasa T, Int J Cancer 2004 112 1029 1035 10.1002/ijc.20517 15386348
30. Identification of a novel SEREX antigen, SLC2A1/GLUT1, in esophageal squamous cell carcinoma. Kuboshima M, Shimada H, Liu TL, Nakashima K, Nomura F, Takiguchi M, Hiwasa T, Ochiai T, Int J Oncol 2006 28 463 468 16391802
31. Serum anti-myomegalin antibodies in patients with esophageal squamous cell carcinoma. Shimada H, Kuboshima M, Shiratori T, Nabeya Y, Takeuchi A, Takagi H, Nomura F, Takiguchi M, Ochiai T, Hiwasa T, Int J Oncol 2007 30 97 103 17143517
32. Clinical proteomics in cancer research-promises and limitations of currenttwo-dimensional gel electrophoresis. Iwadate Y, Curr Med Chem 2008 15 2393 2400 10.2174/092986708785909102 18855668
33. Biomarker discovery: a proteomic approach for brain cancer profiling. Khalil AA, Cancer Sci 2007 98 201 213 10.1111/j.1349-7006.2007.00374.x 17233837
34. PHF3-specific antibody responses in over 60% of patients with glioblastoma multiforme. Struss AK, Romeike BF, Munnia A, Nastainczyk W, Steudel WI, Konig J, Ohgaki H, Feiden W, Fischer U, Meese E, Oncogene 2001 20 4107 4114 10.1038/sj.onc.1204552 11464277
35. Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Tanwar MK, Gilbert MR, Holland EC, Cancer Res 2002 62 4364 4368 12154041
36. Cathepsin D is a potential serum marker for poor prognosis in glioma patients. Fukuda ME, Iwadate Y, Machida T, Hiwasa T, Nimura Y, Nagai Y, Takiguchi M, Tanzawa H, Yamaura A, Seki N, Cancer Res 2005 65 5190 5194 10.1158/0008-5472.CAN-04-4134 15958563
37. High serum level of plasminogen activator inhibitor-1 predicts histological grade of intracerebral gliomas. Iwadate Y, Hayama M, Adachi A, Matsutani T, Nagai Y, Hiwasa T, Saeki N, Anticancer Res 2008 28 415 418 18383878